Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
Open Access
- 28 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 146 (3), 695-704
- https://doi.org/10.1007/s00432-019-03091-y
Abstract
Background Malignant mixed Mullerian tumors of endometrial (MMMT-E) and ovarian (MMMT-O) origin are associated with poor prognosis. Suggestively epithelial-driven tumors, their treatment has shifted from anthracycline or ifosfamide-based towards taxane-based chemotherapy. It remains unclear whether this change associates with better outcomes. Patients and methods A conjoined Australian and Swiss patient cohort of MMMT-E (N = 103) and MMMT-O (N = 17) was compared to patients with adenocarcinoma of the endometrium (EC, N = 172) and ovary (OC, N = 189). Clinicopathological characteristics, FIGO stage, first-line treatment, and patient outcomes were analyzed. The generated hypothesis was verified in an US-American cohort with high-grade serous ovarian cancer (HGSOC, N = 1290) and MMMT-O (N = 450) using immunohistochemistry and next-generation sequencing. Results Early stage I/II MMMT-E showed a survival plateau after 2.5 years, with no recurrence or death observed afterwards. Relapse-free survival was significantly worse in MMMT-E treated with platinum/taxanes (P = 0.024) compared to non-taxane regimen. Hypothesizing that also MMMT-O might benefit from an adjuvant non-paclitaxel regimen, a second independent cohort of MMMT-O and HGSOC patients was examined. p53 mutations dominated in both cancers with comparable frequency. PI3KCA and KRAS mutations were less frequent: they were more frequent in MMMT-O than in HGSOC (P = 0.015 and P = 0.018, respectively). MMMT-O responded better to a combination of carboplatin with anthracyclines than with taxanes (73.9% vs. 39.4%). Conclusion Early stage I/II MMMT-E patients have excellent prognosis if no recurrence has appeared within the first 2.5 years. In MMMT-E, platinum/anthracycline or ifosfamide regimen associated with better outcomes than platinum/taxanes regimens. This might also apply to MMMT-O.Funding Information
- Cancer Institute NSW (09/CRF/2-02)
- RANZCOG Research Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030-156982)
- Oncosuisse (KFS_3013_08_2012)
This publication has 40 references indexed in Scilit:
- A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II ConsortiaGynecologic Oncology, 2012
- The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcomaGynecologic Oncology, 2011
- The Role of Adjuvant Chemotherapy in Surgical Stages I-II Serous and Clear Cell Carcinomas and Carcinosarcoma of the Endometrium: A Collaborative StudyInternational Journal of Gynecologic Cancer, 2011
- The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature reviewArchiv für Gynäkologie, 2010
- The impact of multi-modal therapy on survival for uterine carcinosarcomasGynecologic Oncology, 2010
- A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterusGynecologic Oncology, 2007
- Carcinosarcoma of the ovary treated with platinum and taxane: The memorial Sloan-Kettering Cancer Center experienceGynecologic Oncology, 2007
- Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group studyGynecologic Oncology, 2004
- Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomasInternational Journal of Gynecologic Cancer, 2002